# print(a_json['treatments'])#[{'alterations': ['BCR-ABL1 Fusion'], 'drugs': [{'ncitCode': 'C62035', 'drugName': 'Imatinib', 'uuid': 'f42768c5-4918-4244-98dd-6ea97a4d3c2a', 'synonyms': ['Imatinib', 'IMATINIB', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}], 'approvedIndications': ['Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia'], 'level': 'LEVEL_1', 'levelAssociatedCancerType': {'id': None, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}, 'pmids': ['11287973', '24441288', '12200353'], 'abstracts': [], 'description': ''}, {'alterations': ['BCR-ABL1 Fusion'], 'drugs': [{'ncitCode': 'C62035', 'drugName': 'Imatinib', 'uuid': 'f42768c5-4918-4244-98dd-6ea97a4d3c2a', 'synonyms': ['Imatinib', 'IMATINIB', '4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide']}], 'approvedIndications': ['1) Newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase. 2) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. 3) Pediatric patients with Ph+ CML in chronic phase who are newly diagnosed or whose disease has recurred after stem cell transplant or who are resistant to interferon-alpha therapy.'], 'level': 'LEVEL_1', 'levelAssociatedCancerType': {'id': None, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}, 'pmids': ['11287973', '28095277', '12637609', '11287972'], 'abstracts': [], 'description': ''}, {'alterations': ['BCR-ABL1 Fusion'], 'drugs': [{'ncitCode': 'C38713', 'drugName': 'Dasatinib', 'uuid': 'df40a264-628f-4070-9078-965c0471bd2c', 'synonyms': ['Dasatinib', 'dasatinib', 'Sprycel', 'Dasatinib Monohydrate', 'BMS-354825', 'DASATINIB', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate', 'Dasatinib Hydrate']}], 'approvedIndications': ['Adults or children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.'], 'level': 'LEVEL_1', 'levelAssociatedCancerType': {'id': None, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}, 'pmids': ['17496201', '20131302', '21931113'], 'abstracts': [{'link': '/content/130/Suppl_1/98', 'abstract': 'Hunger et al. ASH 2017'}], 'description': ''}, {'alterations': ['BCR-ABL1 Fusion'], 'drugs': [{'ncitCode': 'C48375', 'drugName': 'Nilotinib', 'uuid': '0f991d49-4cf2-4975-b52f-d7d037aa7f11', 'synonyms': ['Nilotinib', 'AMN 107 Base Form', 'nilotinib', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide', 'NILOTINIB']}], 'approvedIndications': ['1) For the treatment of chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to prior therapy, including imatinib', ' 2) For the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP-CML) 3) for pediatric patients 1 year of age or older with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy.'], 'level': 'LEVEL_1', 'levelAssociatedCancerType': {'id': None, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}, 'pmids': ['20525993', '23502220', '28218239'], 'abstracts': [], 'description': ''}, {'alterations': ['BCR-ABL1 Fusion'], 'drugs': [{'ncitCode': 'C38713', 'drugName': 'Dasatinib', 'uuid': 'df40a264-628f-4070-9078-965c0471bd2c', 'synonyms': ['Dasatinib', 'dasatinib', 'Sprycel', 'Dasatinib Monohydrate', 'BMS-354825', 'DASATINIB', '5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate', 'Dasatinib Hydrate']}], 'approvedIndications': ['For the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in chronic phase (CP-CML).'], 'level': 'LEVEL_1', 'levelAssociatedCancerType': {'id': None, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}, 'pmids': ['27217448', '20525995'], 'abstracts': [], 'description': ''}, {'alterations': ['BCR-ABL1 Fusion'], 'drugs': [{'ncitCode': 'C60809', 'drugName': 'Bosutinib', 'uuid': '80a4278a-4622-45e5-9e3f-8ca98657692f', 'synonyms': ['4-Anilino-3-quinolinecarbonitrile', 'BOSUTINIB', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile', 'SKI 606', 'Bosulif', 'SKI-606', '4-Anilinobenzo(g)quinoline-3-carbonitrile', 'Bosutinib']}], 'approvedIndications': [], 'level': 'LEVEL_1', 'levelAssociatedCancerType': {'id': None, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}, 'pmids': ['29091516', '24345751', '26040495'], 'abstracts': [], 'description': ''}, {'alterations': ['BCR-ABL1 Fusion'], 'drugs': [{'ncitCode': 'C114494', 'drugName': 'Asciminib', 'uuid': '1e3c2981-4cc6-43e7-be76-b479050ebdca', 'synonyms': ['ABL001', 'ASCIMINIB', 'Asciminib']}], 'approvedIndications': [], 'level': 'LEVEL_1', 'levelAssociatedCancerType': {'id': None, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}, 'pmids': ['34407542'], 'abstracts': [], 'description': ''}, {'alterations': ['BCR-ABL1 Fusion'], 'drugs': [{'ncitCode': 'C95777', 'drugName': 'Ponatinib', 'uuid': '122b8921-3cd6-4b57-bdc8-5d39cc5465a1', 'synonyms': ['PONATINIB', 'AP-24534', 'AP24534', 'Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)', 'Ponatinib']}], 'approvedIndications': [], 'level': 'LEVEL_1', 'levelAssociatedCancerType': {'id': None, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}, 'pmids': ['24180494'], 'abstracts': [], 'description': ''}, {'alterations': ['BCR-ABL1 Fusion'], 'drugs': [{'ncitCode': 'C60809', 'drugName': 'Bosutinib', 'uuid': '80a4278a-4622-45e5-9e3f-8ca98657692f', 'synonyms': ['4-Anilino-3-quinolinecarbonitrile', 'BOSUTINIB', '4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile', 'SKI 606', 'Bosulif', 'SKI-606', '4-Anilinobenzo(g)quinoline-3-carbonitrile', 'Bosutinib']}], 'approvedIndications': [''], 'level': 'LEVEL_2', 'levelAssociatedCancerType': {'id': None, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}, 'pmids': ['25132497', '24345751', '26040495'], 'abstracts': [], 'description': ''}, {'alterations': ['BCR-ABL1 Fusion'], 'drugs': [{'ncitCode': 'C48375', 'drugName': 'Nilotinib', 'uuid': '0f991d49-4cf2-4975-b52f-d7d037aa7f11', 'synonyms': ['Nilotinib', 'AMN 107 Base Form', 'nilotinib', '4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide', 'NILOTINIB']}], 'approvedIndications': [], 'level': 'LEVEL_2', 'levelAssociatedCancerType': {'id': None, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}, 'pmids': ['16775235'], 'abstracts': [], 'description': ''}]
